Department of Internal Medicine, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Department of Microbiology and Clinical Parasitology, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Biomed Res Int. 2020 Feb 18;2020:4150678. doi: 10.1155/2020/4150678. eCollection 2020.
Methicillin-resistant (MRSA) is known for serious health problems. Testing new inexpensive natural products such as mango kernel ( L., Anacardiaceae) may provide alternative and economically viable anti-MRSA drugs. In the current study, we screened clinical isolates from Aseer Central Hospital, Saudi Arabia, during 2012-2017 for MRSA and tested an ethanolic extract of mango kernel for anti-MRSA activity. Brief confirmation of MRSA was performed by the Vitek 2 system, while antibiotic sensitivity of strains was tested for their clinical relevance. The disc diffusion method was used to test the anti-MRSA activity of the ethanolic mango kernel extract. The antimicrobial activity of mango kernel was compared to that of standard drugs (oxacillin and vancomycin). Of the identified 132 strains, 42 (31.8%) were found to be MRSA and their prevalence showed a clear increase during the last two years (2016-2017; < 0.001). MRSA strains showed 100% sensitivity to vancomycin, teicoplanin, linezolid, tetracycline, daptomycin, tigecycline, and tobramycin and 100% resistance to ampicillin and 98% to penicillin. The ethanolic extracts of mango kernel were found active against both and the MRSA strains. Inhibitory activities (mean ± SE) were achieved at concentrations of 50 mg/mL (20.77 ± 0.61), 5 mg/mL (16.18 ± 0.34), and 0.5 mg/mL (8.39 ± 0.33) exceeding that of vancomycin (=0.0162). MRSA strains were sensitive to mango kernel extracts when compared to vancomycin. Therefore, ethanolic extracts of mango kernel can be escalated to animal model studies as a promising leading anti-MRSA drug candidate and can be an economic alternative to high-priced synthetic antibiotics.
耐甲氧西林金黄色葡萄球菌（MRSA）已知会引起严重的健康问题。测试芒果核（漆树科）等新的廉价天然产品可能为抗 MRSA 药物提供替代和经济可行的选择。在目前的研究中，我们筛选了 2012 年至 2017 年期间沙特阿拉伯阿西尔中央医院的临床分离株，以检测芒果核的乙醇提取物的抗 MRSA 活性。通过 Vitek 2 系统对 MRSA 进行了简要确认，同时还测试了菌株的抗生素敏感性以评估其临床相关性。采用纸片扩散法检测乙醇芒果核提取物的抗 MRSA 活性。将芒果核的抗菌活性与标准药物（苯唑西林和万古霉素）进行了比较。在所鉴定的 132 株菌株中，发现 42 株（31.8%）为 MRSA，其流行率在过去两年（2016-2017 年）明显增加（<0.001）。MRSA 菌株对万古霉素、替考拉宁、利奈唑胺、四环素、达托霉素、替加环素和妥布霉素 100%敏感，对氨苄西林 100%耐药，对青霉素 98%耐药。芒果核的乙醇提取物对 和 MRSA 菌株均具有活性。在 50mg/mL（20.77±0.61）、5mg/mL（16.18±0.34）和 0.5mg/mL（8.39±0.33）的浓度下可达到抑制活性（均值±SE），超过了万古霉素（=0.0162）。与万古霉素相比，MRSA 菌株对芒果核提取物敏感。因此，乙醇芒果核提取物可以升级为动物模型研究，作为有前途的抗 MRSA 先导药物候选物，并且可以作为高价合成抗生素的经济替代物。
